PDC and Thromboembolism: HIF-PHD inhibitor treatment may also cause thromboembolism, roxadustat caused more thrombosis than ESAs and vadadustat, according to an analysis, and the lowest rates of thrombosis were seen with molidustat and ESAs, with the US FDA raising concern for thrombotic risk of certain HIF-PHD inhibitors (34).